Corporate Risk & Compliance
Zevra Therapeutics faces critical revenue risk tied to single rare disease drug
ViaNews Editorial Team (Finance)•
#rare disease
2 articles
Biotech & Pharmaceuticals
REGENXBIO Eyes 2027 Commercial Launch for Duchenne Gene Therapy as Pivotal Trial Wraps Enrollment
ViaNews Editorial Team (Finance)•